阿西米尼单药治疗既往接受至少两种酪氨酸激酶抑制剂且无BCR::ABL1 T315I突变的慢性期慢性髓性白血病患者的4年1期安全性和疗效结果
报告了一项1期开放标签非随机试验(NCT02081378)的更新结果,评估阿西米尼单药10-200 mg每日一次或两次治疗115例无T315I突变的慢性期慢性髓性白血病患者的安全性和抗白血病活性。中位暴露约4年,69.6%患者仍在治疗,最常见≥3级不良事件为胰腺酶升高(22.6%)、血小板减少(13.9%)、高血压(13.0%)和中性粒细胞减少(12.2%)。
要点
- 中位暴露约4年时69.6%患者仍在接受阿西米尼治疗。
- 最常见≥3级不良事件为胰腺酶升高22.6%、血小板减少13.9%、高血压13.0%、中性粒细胞减少12.2%。
- 临床胰腺炎和动脉闭塞事件分别发生于7.0%和8.7%的患者。
核心结论
- 阿西米尼单药在既往接受至少两种酪氨酸激酶抑制剂且无T315I突变的慢性期慢性髓性白血病患者中显示出长期安全性和疗效。
研究设计与样本
- 1期、开放标签、非随机试验(NCT02081378),纳入115例无T315I突变的慢性期慢性髓性白血病患者,接受阿西米尼单药10-200 mg每日一次或两次,数据截止日期为2021年1月6日。
主要发现
- 中位暴露约4年后,69.6%的患者仍在接受阿西米尼治疗。
- 最常见的≥3级不良事件包括胰腺酶升高(22.6%)、血小板减少(13.9%)、高血压(13.0%)和中性粒细胞减少(12.2%)。
- 所有级别不良事件(大多为1/2级)包括肌肉骨骼疼痛(59.1%)、上呼吸道感染(41.7%)和疲乏(40.9%)。
- 临床胰腺炎和动脉闭塞事件分别发生于7.0%和8.7%的患者。
- 大多数不良事件发生在第1年,后续新发事件(包括动脉闭塞事件)的可能性较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asciminib is approved for patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of a phase 1, open-label, nonrandomized trial (NCT02081378) assessing the safety, tolerability, and antileukemic activity of asciminib monotherapy 10-200 mg once or twice daily in 115 patients with CML-CP without T315I (data cutoff: January 6, 2021). After ≈4-year median exposure, 69.6% of patients remained on asciminib. The most common grade ≥3 adverse events (AEs) included increased pancreatic enzymes (22.6%), thrombocytopenia (13.9%), hypertension (13.0%), and neutropenia (12.2%); all-grade AEs (mostly grade 1/2) included musculoskeletal pain (59.1%), upper respiratory tract infection (41.7%), and fatigue (40.9%). Clinical pancreatitis and arterial occlusive events (AOEs) occurred in 7.0% and 8.7%, respectively. Most AEs occurred during year 1; the subsequent likelihood of new events, including AOEs, was low. By data cutoff, among patients without the indicated response at baseline, 61.3% achieved BCR::ABL1 ≤ 1%, 61.6% achieved ≤0.1% (major molecular response [MMR]), and 33.7% achieved ≤0.01% on the International Scale. MMR was maintained in 48/53 patients who achieved it and 19/20 who were in MMR at screening, supporting the long-term safety and efficacy of asciminib in this population.
引用
- Mauro MJ, Hughes TP, Kim DW, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023. PMID: 36949155. doi:10.1038/s41375-023-01860-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。